Strong Nuclear Orders Announced by Avingtrans
The world has entered a new super-cycle: nuclear power. Surging AI adoption, electricity hungry data centres, geopolitical instability (Ukraine/Iran wars), energy security and the global push for decarbonisation are all converging to create a structural step-change in demand. Crucially, renewables alone can’t fill that gap — which is why governments and Big Tech alike are backing nuclear, particularly next-gen technologies like Small Modular Reactors (SMRs), with billions of dollars of funding and long-term offtake agreements.
Step forward Avingtrans , a specialist picks & shovels engineer supplying (>20% turnover) mission critical components to this buoyant sector. Here, it already supplies high tech pumps for ‘New Nuclear’ (eg Terrapower), fusion & life extensions, alongside high integrity waste storage boxes for decommissioning at Sellafield.
What’s more since January, its Advanced Engineering Systems (AES) division has seen a material uptick in demand. Securing >£10m of nuclear orders, including a £3m Reactor Water Cleanup Pump contract with Iberdrola in Spain and prototype work for next-gen SMRs. Further underpinning market expectations (>95% FY26 revenue cover) and entrenching its technologies within the industry’s core DNA.
Elsewhere in last year’s Spending Review, the UK government committed to its £4bn decommissioning programme - of which 75% has been allocated to Sellafield, one of AES’ largest clients. A further £40bn is also being invested in the new Sizewell C reactor, with President Trump doing the same in the US.
COO Austen Adams commenting: “Avingtrans’ businesses enjoy a distinctive position… from legacy infrastructure to new build and novel technologies… we expect this to be just the start of a significant increase in market activity.”
Wrt the May FY’26 numbers, analysts are forecasting £175m of revenue, £20.5m EBITDA and EPS of 30.4p – rising to £193.3m (+10.5% LFL), £24.5m (19.8%) and 37.4p (+23%) 12 months later. Implying strong double-digit driven by secular tailwinds, operational leverage, improving mix and narrowing losses in the medical division. Thus at 580p, putting the shares on 15.5x May FY’27 PE and 8.5x EV/EBITDA multiples.
Lastly over the next few years, shareholders could also enjoy some hefty capital returns, thanks to possible disposals of Hayward Tyler & Ormandy, coupled with the potential IPO of Medical division.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
